Results 61 to 70 of about 21,988 (154)

The effects of antirheumatic drugs on the production of, and the responsiveness to cytokines (IL-1 and IL-6).

, 1991
Junko Hashimoto, Kazuto Sato, Megumu Higaki, Kusuki Nishioka, Sadao Kashiwazaki, Nobuyuki Miyasaka   +5 more
openalex   +2 more sources

Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics [PDF]

, 2005
Cheryl Carli, Anna Ehlin, Lars Klareskog, Staffan Lindblad, Scott Montgomery   +4 more
openalex   +1 more source

Incidence and Genetic Risk of Juvenile Idiopathic Arthritis in Norway by Latitude

Arthritis &Rheumatology, Volume 77, Issue 4, Page 458-467, April 2025.
Objective We aimed to investigate the incidence of juvenile idiopathic arthritis (JIA) in the three geographic regions of Norway and whether potential regional incidence differences are explained by environmental or genetic factors across regions. Methods We conducted a register‐based cohort study including all Norwegian children born from 2004 to 2019,
Sigrid V. Hestetun, Hamid K. Rudsari, Piotr Jaholkowski, Alexey Shadrin, Kristine L. Haftorn, Svend Andersen, Marite Rygg, Ellen Nordal, Oleksandr Frei, Ole A. Andreassen, Anne M. Selvaag, Ketil Størdal, Helga Sanner   +12 more
wiley   +1 more source

Antirheumatic Drugs and the Risk of Tuberculosis [PDF]

, 2006
Paul Brassard, Abbas Kezouh, Samy Suissa
openalex   +1 more source

Real-World Treatment Effectiveness of Disease-Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis. [PDF]

ACR Open Rheumatol, 2023
Jin Y, Liu J, Desai RJ, Kim SC.
europepmc   +1 more source

Inhibitory effects of TA-383, a novel disease modifying antirheumatic drug(DMARD), on IL-1 production and synovial cell proliferation.

, 1992
Yu Shong Zao, Masao Shingu, Masashi Nobunaga   +2 more
openalex   +2 more sources

Magnetic resonance imaging in patients with rheumatoid arthritis with complete remission treated with disease-modifying antirheumatic drugs or anti-tumour necrosis factor agents [PDF]

, 2006
Marco Ulises Martínez‐Martínez, Enrique Cuevas-Orta, G Reyes-Vaca, Lourdes Baranda, Roberto González‐Amaro, Carlos Abud‐Mendoza   +5 more
openalex   +1 more source

Characterizing Nonarticular Pain at Early Rheumatoid Arthritis Diagnosis: Evolution Over the First Year of Treatment and Impact on Remission in a Prospective Real‐World Early Rheumatoid Arthritis Cohort

Arthritis &Rheumatology, Volume 77, Issue 4, Page 405-413, April 2025.
Objective Our objective was to characterize nonarticular pain (NAP) at early rheumatoid arthritis (RA) diagnosis, the evolution over the first year of treatment, associations with active RA inflammation, and the impact on remission. Methods This real‐world, longitudinal multicenter cohort study observed participants with active early RA (symptoms <1 ...
Charis F. Meng, Yvonne C. Lee, Orit Schieir, Marie‐France Valois, Margaret A. Butler, Gilles Boire, Glen Hazlewood, Hugues Allard‐Chamard, Carol Hitchon, Bindee Kuriya, Diane Tin, Carter Thorne, Louis Bessette, Janet Pope, Susan J. Bartlett, Vivian P. Bykerk, on behalf of the Canadian Early Arthritis Cohort Investigators   +16 more
wiley   +1 more source

Effects of disease modifying antirheumatic drugs on the production of IL-1.ALPHA., IL-1.BETA. and TNF by normal monocytes and mononuclear cells in vitro.

, 1990
Tetsuya Wada, Masasho Singu, Ichiko Ezaki, Masashi Nobunaga   +3 more
openalex   +2 more sources

Early combination disease modifying antirheumatic drug treatment for rheumatoid arthritis [PDF]

, 2006
Lynden Roberts, Leslie G. Cleland, Susanna Proudman, Ranjeny Thomas   +3 more
openalex   +1 more source